Timothy P. Clackson - 06 Oct 2021 Form 3 Insider Report for Theseus Pharmaceuticals, Inc.

Role: President and CEO, Director
Signature: /s/ Bradford Dahms - Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 06 Oct 2021
Net transactions value: $0
Form type: 3
Filing time: 06 Oct 2021, 19:00:14 UTC
Previous filing: 24 Jun 2021
Next filing: 21 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	THRX	Common Stock						345,930	06 Oct 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	THRX	Stock Option (right to buy)							06 Oct 2021	Common Stock	1,037,793	$4.03	Direct	F1
holding	THRX	Stock Option (right to buy)							06 Oct 2021	Common Stock	110,790	$4.03	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on April 15, 2022 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.
F2	The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after May 27, 2021, subject to the Reporting Person's continuous service with the issuer.